IL-6 levels have been shown to be elevated within the tumour micro-environment (TME) of DLBCL, where it is produced by reactive immune and stromal cells (particularly macrophages and endothelial cells) (Emilie et al., 1992), as well as by the tumour cells directly. The gene discussed is IL6; the disease is neoplasm.